High-Resolution Ocular Imaging: Combining Advanced Optics and Microtechnology by Cordeiro, M. Francesca et al.
High-Resolution Ocuar Imaging: Combining Advanced Optics
and Microtechnology
M. Francesca Cordeiro, MD, PhD,
Address correspondence to M. Francesca Cordeiro, MD, PhD, UCL Institute of Ophthalmolog y, Bath Street, London EC1V 9EL,
United Kingdom.
Presented in part at the annual Optic Nerve Rescue and Restoration Think Tank, New York, New York, September 28-29, 2007.
The authors have no financial or proprietary interest in the materials presented herein.
Optic Nerve Rescue and Restoration Think Tank Attendees
The annual Optic Nerve Rescue and Restoration Think Tank, sponsored by The Glaucoma Foundation, was entitled “High Resolution
Imaging of the Eye: Advanced Optics, Microtechnology and Nanotechnology” and held in New York, NY, September 28-29, 2007.
The meeting organizers and moderators were Robert Ritch, MD (Professor and Chief, Glaucoma Services, New York Eye and Ear
Infrmary, New York, NY), Terete Borrás, PhD (Professor of Ophthalmology, University of North Carolina at Chapel Hill, Chapel
Hill, NC), M. Francesca Cordeiro, PhD (Professor, UCL Institute of Ophthalmology & Western Eye Hospital, London, England),
Wolfgang Drexler, PhD (Professor, Cardiff University, Cardiff, Wales), Jost Jonas, MD (Professor and Chairman, Department of
Ophthalmology, Ruprecht-arls-University Heidelberg, Mannheim, Germany), Jeffrey M. Liebmann, MD (Clinical Professor of
Ophthalmology, Manhattan Eye, Ear & Throat Hospital, New York, NY), Georg Michelson, PhD (Professor of Ophthalmology,
Friedrich-Alexander University, Erlangen, Germany), and Robert Nickells, PhD (Associate Professor, University of Wisconsin
Medical School, Madison, WI).
Participants included Victor Barocas, PhD (Associate Professor and Director of Graduate Studies, Department of Biomedical
Engineering, University of Minnesota, Minneapolis, MN), Steven Bassnett, PhD (Associate Professor, Department of Ophthalmology
and Visual Sciences, Washington University in St. Louis, MO), Bruce Berkowitz, PhD (Professor, Anatomy and Cell Biology, School
of Medicine, Wayne State University, Detroit, MI), Prof. Dr. Josef Bille (University of Heidelberg, Institute of Applied Physics,
Heidelberg, Germany), Michael Boulton, PhD (Professor, Ophthalmology and Visual Sciences, University of Texas, Galveston, TX),
Kevin M. Brindle, PhD (Professor, Cambridge Centre for Brain Repair, University of Cambridge, UK), Claude Burgoyne, MD (Senior
Scientist and Research Director, Optic Nerve Head Biomechanics Laboratory, Devers Eye Institute, Portland, OR), John Danias, MD,
PhD (Assistant Professor, Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY), Robert O. Duncan, PhD
(Assistant Project Scientist, Hamilton Glaucoma Center, University of California, San Diego, CA), Rutledge Ellis-Behnke, PhD
(Primary Investigator, Department of Brain and Cognitive Science, MIT, Cambridge, MA), Murray Fingeret, OD (Professor, SUNY
College of Optometry, Hewlett, NY), James Fujimoto, PhD (Professor of Electrical Engineering, MIT, Cambridge, MA), Amiram
Grinvald, PhD (Professor, Neurobiology Department, Weizmann Institute of Science, Rehovot, Israel), Gregory K. Harmon, MD
(Chairman, The Glaucoma Foundation, New York, NY), Elizabeth M. C. Hillman, PhD (Assistant Professor, Department of
Biomedical Engineering, Columbia University, New York, NY), Hiroshi Ishikawa, MD (Assistant Professor, Departments of
Ophthalmology and Bioengineering, University of Pittsburgh, Pittsburgh, PA), Joseph Izatt, PhD (Associate Professor of Biomedical
Engineering and Ophthalmology, Duke University, Durham, NC), James Jester, PhD (Visiting Professor, Biomedical Engineering,
Ophthalmology, University of California, Irvine, CA), Paul Kaufman, MD (Professor and Chair, Department of Ophthalmology,
University of Wisconsin, Madison, WI), Chris Leung, MD (Clinical and Research Fellow, Department of Ophthalmology, Hamilton
Glaucoma Center, University of California, San Diego, CA), Carlo D. Montemagno, PhD (Dean, College of Engineering, University
of Cincinnati, Cincinnati, OH), Stephen Obstbaum, MD (Chairman, Department of Ophthalmology, Lenox Hill Hospital, New York,
NY), Nathan Radcliffe, MD (Clinical Glaucoma Fellow, New York Eye and Ear Infirmary, New York, NY), Richard Rosen, MD
(Professor and Vice Chairman, Department of Ophthalmology, New York Eye and Ear Infirmary, New York, NY), Stephen J. Smith,
PhD (Professor, Department of Molecular & Cellular Physiology, Stanford University, Stanford, CA), James C. Tsai, MD (Robert R.
Young Professor and Chairman, Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT),
Joseph B. Walsh, MD (Professor and Chairman, Department of Ophthalmology, New York Eye and Ear Infirmary, New York, NY),
John S. Werner, PhD (Professor, Department of Ophthalmology and Visual Science, University of California–Davis, Sacramento,
CA), Linda Zangwill, PhD (Professor, Shiley Eye Center, University of California, San Diego, CA), Marco Zarbin, MD, PhD
(Professor and Chair, Institute of Ophthalmology and Visual Science, New Jersey Medical School, Newark, NJ), Shuguang Zhang,
PhD (Principal Investigator & Associate Director, Department of Biology, MIT, Cambridge, MA), Ralph Barbeito, PhD (Pfizer, Inc.,
New York, NY), James Burke, BS (Allergan, Inc., Irvine, CA), Zuhal Butuner, OD, MSc, MBA (QLT, Inc., Vancouver, BC), Cherry
Chen, BS, EMBA (Life Spring Biotech Co., Ltd., Taipei, Taiwan), Wei-Cherng Hsu, MD (Life Spring Biotech Co., Ltd., Taipei,
Taiwan), Elizabeth Kim, MD (Pfizer, Inc., New York, NY), Scott Meyer, PhD (Carl Zeiss Meditec, Inc., Dublin, CA), Modestus
Obochi, PhD, MBA (QLT, Inc., Vancouver, BC), Miller J. Ogidigben, PhD (Merck Research Laboratories, West Point, PA), Richard
L. Ornberg, PhD (Alcon Research, Ltd., Fort Worth, TX), Samuel Santander, MD, MPH (Bausch & Lomb, Rochester, NY), Catherine
Thut, PhD (Merck Research Laboratories, West Point, PA), Charles S. Tressler, MD (Pfizer, Inc., New York, NY), Martin B. Wax,
MD (Alcon Research Laboratories, Inc., Fort Worth, TX), and Qienyuan Zhou, PhD (Carl Zeiss Meditec, Inc., San Diego, CA).
NIH Public Access
Author Manuscript
Ophthalmic Surg Lasers Imaging. Author manuscript; available in PMC 2014 August 27.
Published in final edited form as:






















UCL Institute of Ophthalmology and Western Eye Hospital, London, United Kingdom
Robert Nickells, PhD,
Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin
Wolfgang Drexler, PhD,
Department of Optometry and Visual Sciences, Cardiff University, Cardiff, Wales, United
Kingdom
Terete Borrás, PhD, and
Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina
Robert Ritch, MD
Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York;
Department of Ophthalmology, New York Medical College, Valhalla, New York
Abstract
Recent developments in imaging technologies offer great potential for the assessment of retinal
ganglion cell disorders, with particular relevance to glaucoma. In particular, advances in this field
have allowed unprecedented in vivo access to the retinal layers, using many different properties of
light to differentiate cellular structures. This article is a summary of currently available and
investigational advanced, high-resolution imaging technologies and their potential applications to
glaucoma. It represents the topics of discussion at the annual Optic Nerve Rescue and Restoration
Think Tank, sponsored by The Glaucoma Foundation, entitled “High Resolution Imaging of the
Eye: Advanced Optics, Microtechnology and Nanotechnology” and held in New York, New York,
September 28-29, 2007.
Introduction
Glaucoma is a leading cause of irreversible blindness worldwide. Loss of vision is caused by
progressive retinal ganglion cell and axonal death, resulting in a characteristic pattern of
optic nerve head and visual field loss.1 Because glaucoma is a silent and insidious disease,
patients often present late in its course, when significant visual loss has already occurred.
Furthermore, the gold standard of diagnosing glaucomatous visual field loss by standard
automated perimetry detects disease only after a significant proportion of retinal ganglion
cells have already been lost,2 corresponding to a 10-year delay in diagnosis.3
Currently, lowering intraocular pressure, the most important known risk factor for
glaucomatous damage, is the only available therapy for the treatment of glaucoma.4
Unfortunately, patients can continue to lose vision despite apparently successful intraocular
pressure control. This has highlighted the need for alternative treatment approaches.5
However, the evaluation of potential neuroprotective strategies that do not rely on lowering
intraocular pressure requires both better defined clinical end points and earlier and better
detection and measures of progression. An “ideal” end point in glaucoma would be one that
could directly measure retinal ganglion cell dysfunction and disease.
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From an anatomic perspective, new noninvasive imaging technologies6,7 to identify early
changes in the retinal nerve fiber layer and optic nerve head would be valuable. Reaching
this goal requires both advances in the resolution of existing technologies and a better
understanding of the changes occurring in the optic nerve, including the temporal ordering
of these changes. Recent advances in biomechanical engineering suggest that changes in
deformation of the lamina cribrosa may provide a quantifiable measure of early
glaucomatous changes.8-12
Similarly, our understanding of changes in glial cell behavior and molecular profiles in the
optic nerve head may provide biological markers for early changes in this tissue. From a
cellular perspective in the retina, it would be valuable to understand the molecular changes
associated with both axonal degeneration and retinal ganglion cell soma loss. For example,
defining early morphological changes in the retinal ganglion cell soma, such as changes in
cell volume, may be detectable. Alternatively, defining metabolic changes, such as
differences in energy metabolism or ion channel conductance, may provide markers that
could be monitored as markers of retinal ganglion cell function. It is important to verify
further the relative timing of events of retinal ganglion cell dysfunction as they occur in the
apoptotic pathway so that we can concentrate on events that precede the irreversible stages
of cellular degeneration. Essentially, we need to ask what changes occur in affected retinal
ganglion cells that may be reversible, thus allowing for better resolution of the effects of
protective strategies?
Recent developments in imaging technologies offer great potential for the assessment of
retinal ganglion cell disorders, with particular relevance to glaucoma. In particular, advances
in this field have allowed unprecedented in vivo access to the retinal layers, using many
different properties of light to differentiate cellular structures. The following is a summary
of currently available and investigational advanced, high-resolution imaging technologies
and their potential applications to glaucoma.
Optical Coherence Tomography
Optical coherence tomography (OCT) is probably the technology that has seen the greatest
recent advances in clinical imaging. It uses a low coherence interferometry-based system to
measure changes in refectivity at very high spatial resolution.13 OCT has been increasingly
used in ophthalmology since 1991, with more than 67 companies now producing OCT-based
products for ophthalmic use. Its role in the assessment of macular disease is well
established, and in glaucoma it has been advocated for its potential in measuring thicknesses
of the retinal layers, including the retinal nerve fiber layer thickness.14-19
Three-Dimensional OCT
This conventional method of OCT uses a moving reference arm to obtain axial information,
with the limitation being the speed of scanning. Increasing the speed has led to great
improvements in three-dimensional (3D) imaging capabilities, where a series of multiple x-y
scans are reconstructed in the z plane. This has directed the development of “optical biopsy”
or “virtual surgery” of retinal pathology.20-23 Three-dimensional OCT produces detailed and
striking images of retinal pathology, as illustrated so convincingly by Choi et al.23 and
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Drexler.24 Cross-sectional en-face views and rendering from a virtual perspective provides
the potential of measuring changes in the retinal nerve fiber layer over time, using 3-D OCT.
However, this method still cannot be used to visualize individual retinal ganglion cells, and
it is recognized that further development is needed to establish the capability of this method
in glaucoma.
Ultra-High Resolution OCT
Ultra-high resolution OCT achieves much higher spatial resolution, of the order of 2 to 3
μm, compared to standard OCT.25 Unlike conventional OCT, which uses monochromatic
visible light, ultra-high resolution OCT uses a wide-band light source. The use of
femtolasers as the light source improves the resolution even more,26-29 but the cost of
femtolasers currently makes it difficult for them to be used on a wide scale.
Fourier or Spectral Domain OCT
Another modification of OCT is Fourier domain or spectral domain OCT. These machines
use a spectroscope to analyze the intensity of each wavelength making up the beam
independently. Because this methodology does not rely on the speed of a moving arm for
each scan, acquisition of images is much faster. High-definition images of the retina and
optic nerve head have been obtained with this technology, with image sizes of up to 10,000
pixels.30-34 However, there are limitations because the sensitivity of the technique varies
with depth and tissue thickness, and the limit of depth range is currently 1.5 mm. Because
this is an emerging technology, new approaches have been used (eg, use of a sweeping laser
source that produces 236,000 scans/sec, which is 500 times faster than conventional CT).
The power of this technology can be illustrated by the fact that individual red blood cells can
be imaged in vivo in a quail's beating heart.35
Adaptive Optics OCT
Adaptive optics was originally developed by astrophysicists to improve visualization of
outer space. By correcting for optical aberrations in real time using a deformable mirror,
adaptive optics can reduce noise at high resolutions. The technique has been applied to both
OCT and scanning laser ophthalmoscopy. Both Drexler and Werner have applied this
technique to ultra-high resolution OCT with impressive results, especially in the imaging of
the photoreceptor outer segments.21,32,36-38 Adaptive optics OCT has also shown
impressively that it is possible to perform functional assays, so-called “optophysiology,”
which relies on measuring the backscatter produced by a light flash on the retina.39 The
potential of this technology for use in glaucoma and retinal ganglion cell assessment is
under development.
Indeed, the major drawback in all OCT methodologies appears to be that the low contrast of
the retinal ganglion cells and retinal nerve fiber layer makes them inherently difficult to
image compared to the photoreceptors. In the future, software developments aimed
specifically at assessing retinal nerve fiber layer or retinal ganglion cell quantification may
allow OCT to assist in providing new clinical end points in clinical glaucoma research, but
significantly more validation will need to be done first. There is a clear need for more
sophisticated analysis. To this end, Fujimoto has urged that an open-access database be
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made available containing OCT images acquired from anonymous patients with glaucoma
and to which interested experts could assess their own analytical methods, rather like the
NIH sponsored Biological Biochemical Image Database.40 However, this method cannot be
used to visualize individual retinal ganglion cells, and it is recognized that further
development is needed to establish the capability of this method in glaucoma.
Spectral Domain Phase Microscopy
Spectral domain phase microscopy (SDPM), an OCT-based imaging technique, is an
extension of Fourier domain OCT with spectral interferometry with a common-path
geometry to depth-resolve nanometer-scale axial displacement and motion in living cells
with millisecond temporal resolution.41,42 Simplistically, it allows the monitoring of the
phase of the fringes in coherence length. Quantitative phase microscopy allows depth
measurement depending on where the phase is measured from. For example, Izatt has
demonstrated that the thickness of a coverslip can be measured to a resolution of less than
one atom using SDPM.43 High-speed cross-sectional SDPM is much faster, with 40 images
acquired per second. It has been used to show spontaneously beating cardiac cells and
migrating pseudopodia of moving cells in culture.
Izatt's research group has shown intricate details of retinal images using SDPM in vivo.44,45
Due to the rapid acquisition of images, motion artifact is eliminated, so photoreceptors,
separate retinal pigment epithelium, Bruch's membrane, outer limiting membrane, and
choriocapillaris may all be studied in great depth. For example, changes associated with
photo-bleaching may be detected as a change in the index of refraction of photoreceptor
cone outer segments.
SDPM has also been used for monitoring neuronal activation, with its ability to look at small
displacements.46 Of great potential in glaucoma is its ability to assess the swelling of
individual axons accompanying action potential propagation at levels of 20-nm
displacement. As with ultra-high resolution OCT and Fourier domain OCT, problems
currently associated with this technology lie in dealing with the large data sets produced and
the need for disease-orientated automated analysis.
High-Resolution Functional Imaging of the Retina
This modified fundus camera uses a stroboscopic flash to capture small videos comprising 8
frames of retinal images 20 to 500 msec apart. Videoanalysis of changes over time enables
assessment of blood flow and functional signals.47 Visualization of movement of single
blood cells allows creation of an enhanced retinal vascular map and measurement of blood
flow. Grinvald has suggested that there is a 40% reduction in blood velocity in patients with
glaucoma compared to control subjects (A. Grinvald, PhD, personal communication,
September 2007).
Another application of this technique is its use as a functional assay. By projecting an
illuminated stimulus on to the retina, a “darkening” signal is observed with infrared light in
areas of retinal stimulation and a “bright” signal in areas of activation.
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A recent finding has been a “nerve fiber” signal arising from the activated area radiating to
the optic disc. This follows the pattern of the arcuate fibers in the papillomacular bundle. On
functional activation with the illuminated stimulus, it appears that there is a “darkening”
around the optic disc in patients with glaucoma. The significance of this has not yet been
elucidated, but it may offer another potential imaging parameter in glaucoma.
Magnetic Resonance Imaging
Functional magnetic resonance imaging (MRI) and enhanced MRI are commonly used in
the assessment of central nervous system disease. Research48-50 has shown that retinal
functional MRI could show functional responses in a cat. This technique has several
applications relevant to glaucoma.51 Duncan et al.52 have shown it possible to assess
neuronal activity associated with glaucoma using functional MRI. In patients with glaucoma
who have definite visual field defects (using standard white-on-white perimetry and short
wavelength automated perimetry), scotoma mapping with a checkerboard stimulus
correlated positively (r = 0.91, P = .01) with functional MRI arterial spin labeling and pulse
sequence diagrams. They have also correlated vision loss in glaucoma with alterations in
cerebral blood flow in the V1 area of the visual cortex.
Manganese-Enhanced MRI
In animal models, manganese injections reveal retinal cellular metabolic activity through the
ability of manganese to serve as a calcium ion surrogate.53 Berkowitz et al.54 and Luan et
al.55 have measured intraretinal thickness and ion channel permeation in vivo and, in
different glaucoma models, demonstrated it possible to measure changes in anterior chamber
angle, ciliary body area, optic nerve head width, and eye circumference.
Using manganese-enhanced MRI, Ellis-Behnke et al.56 and Guo et al.57 have successfully
assessed the progression of functional regeneration of the visual system in vivo in a hamster
optic tract regeneration model using a self-assembling peptide nanofiber scaffold to facilitate
reconstruction of the tissue substrate that supports regeneration across the tissue disruption.
Longitudinal follow-up of the model with sequential manganese-enhanced MRI
preoperatively and immediately postoperatively and 2 and 4 weeks postoperatively revealed
visibly discernible regenerating axons in the superior colliculus of treated animals after 2
weeks. It is suggested that manganese-enhanced MRI may have the potential to measure the
impact of regenerative treatments in optic nerve diseases such as glaucoma prior to any
signs of functional return of behavior.
MRI Imaging of Cell Death and Cell Tracking
One of the better methods of detecting apoptosis in vivo uses the highly specific binding of
synaptotagmin I to phosphatidylserine. Superparamagnetic iron oxide labeling of the C2
domain of synaptotagmin I has been previously used with MRI.58 Neves et al.59 and
Dunning et al.60 have used the C2A domain conjugated to nanoparticles to demonstrate
tumor response to treatment. A recent advance has been the use of gadolinium-tagged GST-
C2, although the group is engineering derivatives of the agent to further increase specificity
and sensitivity. Single cell visualization is not yet possible with this technique.58,61-63
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However, a secondary area of research has been the use of MRI to track individual cells
labeled with different nanoparticles in vivo. This has included tracking stem cells following
their implantation into the brain and spinal cord.
Array Tomography
Array tomography uses modern optical fluorescence and electron microscopy to perform 3D
reconstruction of immunofluorescence-stained serial ultrathin (50 to 200 nm) sections.64
Tissue sections are cut after embedding in a hydrophilic acrylic resin. Continuous ribbons of
hundreds of serial sections on a glass slide form a two-dimensional array, which is then
stained using labeled antibodies and/or other reagents. Fluorescence microscopy of stained
sections is then performed, followed by alignment and collation of individual two-
dimensional section images into volumetric image stacks. The method is even more exciting
because large numbers of immunostains through repeated cycles of staining, imaging, and
stripping individual array slides may be performed without loss of antigenicity.
This method has been used for high-throughput single-synapse analysis of mouse cerebral
cortex, using synaptic molecular markers such as synapsin-I, GABA, Vglut1, Vglut2,
Vglut3, and PSD-95. Smith et al. have computed large differences in synaptic density
varying from 0.7 synapses per cubic millimeter in the somatosensory mouse cortex to 0.4
synapses per cubic millimeter in layer VI and 1 synapse per cubic millimeter in layer I.65
Although this method is histological, it offers great potential in elucidating retinal neuronal
anatomy in glaucoma.
Detection of Apoptosing Retinal Cells
Detection of apoptosing retinal cells (DARC) uses fluorescently labeled annexin V and
fluorescent ophthalmoscopy6,7 to enable direct visualization of retinal ganglion cell death.
Using glaucoma-related experimental models, it is a useful, noninvasive real-time imaging
technique to visualize single retinal ganglion cells undergoing apoptosis in vivo.7,66
Apoptosis is an early cellular process in glaucoma, preceding the exponential rate of retinal
ganglion cell loss responsible for irreversible blindness. DARC enables the longitudinal
study of glaucomatous cellular disease frsthand, which has not previously been possible.6 It
promises to be an invaluable tool for this condition, not only in the diagnosis and screening
of patients, but also in the tracking of disease and the rapid and objective assessment of
potential therapies.
DARC has already been used to assess neuroprotective strategies in experimental models.5 It
is hoped that in addition to helping diagnose early disease, assess progression, and monitor
response to treatment in patients with glaucoma, it may also serve as a new method of
assessing central nervous system degeneration. In short, DARC may provide the biomarker
that we have been searching for and undoubtedly need in glaucoma.
Three-Dimensional Histomorphometry of the Optic Nerve Head
Optic nerve head cupping in glaucoma has been assumed to be a manifestation of prelaminar
neural tissue thinning combined with thinning and deformation of the lamina cribrosa within
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the neural canal.67 Burgoyne used 3D histomorphometric reconstruction of perfusion fixed
optic nerve head tissues to show that an early sign of glaucoma is in fact thickening, not
thinning, of the prelaminar neural tissues and lamina.11 This could potentially be a new
target for clinical 3D OCT optic nerve head imaging in patients at risk for the onset or
progression of glaucomatous damage, as early data by Werner et al. suggest.68,69
Multiphoton Microscopy of the Optic Nerve Head
The development of femtosecond lasers and their ability to interact with different tissues to
induce two-photon fluorescence signals, with second harmonic generated signals and laser-
induced optical breakdown, has been increasingly recognized as a powerful tool in
ophthalmology. Jester has shown their use in determining corneal stromal lamellar
organization, optic nerve head structure, and ocular biomechanical properties.70
Second harmonic generated signals imaging microscopy provides a new approach to 3D
evaluation of the collagen structure of the eye, and holds promise in determining
biomechanical strength and rigidity of the cornea, retina, and optic nerve head. Recent
studies have demonstrated that second harmonic generated signals from collagen allow for
direct optical imaging of the lamina cribrosa.71 This structure is believed to be important
because retinal ganglion cell axonal transport blockade in glaucoma (according to the
mechanical theory) is believed to occur at the level of the lamina cribrosa.72,73 It appears
that the collagen signal at the optic nerve head is reduced in glaucoma. In addition, there is
increasing evidence that laminar pore size is altered in glaucoma, with peripheral and
midperipheral pores being more susceptible to collapse under elevated intraocular pressure.
Two-Photon Microscopy
Using the principles of two-photon imaging, with second harmonic generated signals, and
two-photon excited fluorescence imaging explained above, a two-photon ophthalmoscope
based on the architecture of a conventional fast scanning laser ophthalmoscope has been
developed.74 Two-photon excited fluorescence potentially offers multiple advantages
compared to single-photon fluorescence microscopy, including intrinsic 3D resolution,
larger sensing depth, and reduced photodamage.
Several studies have confirmed that endogenous fluorophores in the human retina alter with
age and disease. Two-photon excited fluorescence provides an opportunity to see this more
clearly, with evidence that single lipofuscin granules accumulating on the retinal pigment
epithelial cells and the retinal nerve fiber layer can be visualized in postmortem human
donor eyes.74-76
Conclusion
These are exciting times in ophthalmic imaging, with great prospects of new clinical end
points being defined. By providing objective, quantifiable, and relevant measurements, it is
hoped that we will soon have a reliable, imaging-based parameter that can be used for
screening, assessment of treatment, and clinical guidance in glaucoma. We are on the brink
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of developing a new generation of tools that will provide us with noninvasive methods of
determining neurodegenerative processes in glaucoma.
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